The French pharmaceutical giant reported $1.29 earnings per share in Q3, exceeding the $1.18 predicted. Net sales increased 10.1% to $12.31bn thanks to eczema medication Dupixent and vaccines, with the US seeing the strongest growth.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.